| Jul 11 |
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data
|
| Jul 2 |
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
|
| Jun 24 |
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)
|
| Jun 13 |
Results of Annual General Meeting
|
| Jun 10 |
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
|
| Jun 6 |
Biodexa Pharmaceuticals files to sell 2.49B ordinary shares for holders
|
| Jun 3 |
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
|
| May 22 |
Biodexa Pharmaceuticals receives $7M of gross proceeds
|
| May 22 |
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
|
| May 21 |
Biodexa rallies 80% on positive Phase 2 data for eRapa
|
